Oragenics Enters Agreement With Lantern Bioworks For Replacement-Therapy Assets; Co. Received $50K Cash Payment Alongside Opportunity To Acquire 1M Shares Of Lantern Equity, Lantern Committed To Pay 10% Royalty On Net Income Generated From Assets
Portfolio Pulse from Bill Haddad
Oragenics has entered into an agreement with Lantern Bioworks for replacement-therapy assets. Oragenics received a $50K cash payment and the opportunity to acquire 1M shares of Lantern equity. Lantern has committed to pay a 10% royalty on net income generated from the assets.
September 29, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oragenics' agreement with Lantern Bioworks could provide a new revenue stream through royalties and potential equity gains from Lantern shares.
The agreement with Lantern Bioworks provides Oragenics with a cash payment and potential equity in Lantern, which could increase Oragenics' asset base and provide a new revenue stream through royalties. This could positively impact Oragenics' financial performance and, consequently, its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100